Sustained antinociceptive effect of cannabinoid receptor agonist WIN 55,212-2 over time in rat model of neuropathic spinal cord injury pain

Journal of Rehabilitation Research and Development

Volumn 46, Issue 1, 2009, Pages 135-144

  Hama, Aldric ^a,b   Sagen, Jacqueline ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Allodynia; Alternative medicine; Chronic pain; Natural product; Neuropathic pain; Opiate; Rat model; Rehabilitation; Spinal cord injury; Tolerance

Indexed keywords

ALLODYNIA; ALTERNATIVE MEDICINE; CHRONIC PAIN; NATURAL PRODUCT; NEUROPATHIC PAIN; OPIATE; RAT MODEL; REHABILITATION; SPINAL CORD INJURY; TOLERANCE;

DOSIMETRY; ELECTRIC CIRCUIT BREAKERS; MEDICINE; PATIENT REHABILITATION;

RATS;

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; MORPHINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; MALE; NERVE COMPRESSION; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE STIMULATION; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; SPINAL CORD INJURY; TACTILE STIMULATION; THERMAL STIMULATION; TREATMENT DURATION;

ANALGESICS, OPIOID; ANIMALS; BENZOXAZINES; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOT TEMPERATURE; MALE; MORPHINE; MORPHOLINES; NAPHTHALENES; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; SPINAL CORD INJURIES;

EID: 65949107529     PISSN: 07487711     EISSN: 07487711     Source Type: Journal    
DOI: 10.1682/JRRD.2008.04.0049     Document Type: Article

References (53)

1. Little JW, Goldstein B, Hammond MC. Spinal cord injury rehabilitation. In: Dillingham TR, Belandres PV, editors. Vol.1, Textbook of military medicine. Washington (DC): The Borden Institute; 1998. p. 161-205.
2. Cloonan CC. Immediate care of the wounded. Wilmette (IL): Brookside; 2007. p. 246.
3. Strauss DJ, Devivo MJ, Paculdo DR, Shavelle RM. Trends in life expectancy after spinal cord injury. Arch Phys Med Rehabil. 2006;87(8):1079-1085
4. Rintala DH, Holmes SA, Fiess RN, Courtade D, Loubser PG. Prevalence and characteristics of chronic pain in veterans with spinal cord injury. J Rehabil Res Dev. 2005;42(5):573-584
5. Widerström-Noga EG, Felipe-Cuervo E, Broton JG, Duncan RC, Yezierski RP. Perceived difficulty in dealing with consequences of spinal cord injury. Arch Phys Med Rehabil. 1999;80(5):580-86.
6. Botterell EH, Callaghan JC, Jousse AT. Pain in paraplegia: Clinical management and surgical treatment. Proc R Soc Med. 1954;47(4):281-288
7. Holmes G. Pain of central origin: Contributions to medical and biological research. New York (NY): Hober; 1919.
8. Kennedy RH. The new viewpoint toward spinal cord injuries. Ann Surg. 1946;124(6):1057-62. [PMID: 17858895] DOI:10.1097/00000658-194612000-194700007
9. Samsa GP, Patrick CH, Feussner JR. Long-term survival of veterans with traumatic spinal cord injury. Arch Neurol. 1993;50:909-914
10. Siddall PJ, Loeser JD. Pain following spinal cord injury. Spinal Cord. 2001;39(2):63-73.
11. Burchiel KJ, Hsu FP. Pain and spasticity after spinal cord injury: Mechanisms and treatment. Spine. 2001;26(Suppl 24):S146-60. [PMID: 11805622] DOI:10.1097/00007632-200112151-200200024
12. Finnerup NB, Jensen TS. Spinal cord injury pain-Mechanisms and treatment. Eur J Neurol. 2004;11(2):73-82.
13. Finnerup NB, Johannesen IL, Sindrup SH, Bach FW, Jensen TS. Pain and dysesthesia in patients with spinal cord injury: A postal survey. Spinal Cord. 2001;39(5):256-262
14. Iversen L, Chapman V. Cannabinoids: A real prospect for pain relief? Curr Opin Pharmacol. 2002;2(1):50-55.
15. Hama A, Sagen J. Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury. Exp Neurol. 2007;204(1):454-457
16. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain. 2004;8(2):173-77. [PMID: 14987627] DOI:10.1016/S1090-3801(03) 00084-93 (Pubitemid 38325885)
17. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819 [PMID: 16186518] DOI:10.1212/01.wnl.0000176753.45410.8b (Pubitemid 41362120)
18. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001;323(7303):13-16.
19. Levy R, Leiphart J, Dills C. Analgesic action of acute and chronic intraspinally administered opiate and α-2-adrenergic agonists in chronic neuropathic pain. Stereotact Funct Neurosurg. 1994;62(1-4):279-289
20. De Vry J, Jentzsch KR, Kuhl E, Eckel G. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol. 2004;15(1):1-12.
21. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53(1):55-63.
22. Hama A, Sagen J. Behavioral characterization and effect of clinical drugs in a rat model of pain following spinal cord compression. Brain Res. 2007;1185:117-128
23. Tallarida RJ, Murray RB. Manual of pharmacological calculations with computer programs. New York (NY): Springer- Verlag; 1981. p. 150.
24. Millan MJ. The induction of pain: An integrative review. Prog Neurobiol. 1999;57(1):1-164.
25. Mechoulam R. The pharmacohistory of cannabis sativa. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton (LA): CRC Press; 1986. p. 1-19.
26. Azad SC, Rammes G. Cannabinoids in anaesthesia and pain therapy. Curr Opin Anaesthesiol. 2005;18(4):424-427
27. Lichtman AH, Martin BR. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav. 1997;57(1-2):7-12.
28. Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K. The neurobiology of cannabinoid analgesia. Life Sci. 1999;65(6-7):665-73.
29. Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56(11):1059- 1068
30. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabisbased medicine. Chem Biodivers. 2007;4(8):1729-1743
31. Wallace M, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007;107(5):785-796
32. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology. 2007;68(7):515-521
33. Hollister LE, Gillespie HK, Ohlsson A, Lindgren JE, Wahlen A, Agurell S. Do plasma concentrations of Δ9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol. 1981;21(8-9 Suppl):171S-77S.
34. Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK. Pharmacological characterization of novel water-soluble cannabinoids. J Pharmacol Exp Ther. 2006;318(3):1230-1239
35. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther. 1996;278(3):989-999
36. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC, Chippari SM, Grego JD, Kullnig RK, Daley GT. Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem. 1992;35(1):124-135
37. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 2001;92(1-2):91-100.
38. Smith FL, Fujimori K, Lowe J, Welch SP. Characterization of Δ9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav. 1998;60(1):183-91.
39. 2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J Pharmacol Exp Ther. 2004;310(2):620-632
40. Costa B, Colleoni M, Conti S, Trovato AE, Bianchi M, Sotgiu ML, Giagnoni G. Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol. 2004;141(1):4-8. [PMID: 14662732] DOI:10.1038/sj.bjp.0705587
41. Lim G, Sung B, Ji RR, Mao J. Upregulation of spinal cannabinoid-1- receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain. 2003;105(1-2):275-83.
42. Siegling A, Hofmann HA, Denzer D, Mauler F, De Vry J. Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol. 2001;415(1):R5-7.
43. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain. 2006;126(1-3):102-114
44. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci. 1976;282:221-239
45. Yaksh TL, Hua XY, Kalcheva I, Nozaki-Taguchi N, Marsala M. The spinal biology in humans and animals of pain states generated by persistent small afferent input. Proc Natl Acad Sci U S A. 1999;96:7680-7686
46. Zhang J, Hoffert C, Vu HK, Groblewski T, Ahmad S, O'Donnell D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci. 2003;17(12):2750-2754
47. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol. 2001;133(4): 586-594
48. Liu C, Walker JM. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. J Neurophysiol. 2006;96(6):2984-2994
49. Yu W, Hao JX, Xu XJ, Wiesenfeld-Hallin Z. The development of morphine tolerance and dependence in rats with chronic pain. Brain Res. 1997;756(1-2):141-46.
50. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology. 2002;58(4):554-563
51. Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: Implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain. 1995;61(3):353-64.
52. Sim-Selley LJ, Martin BR. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]-1,4- benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther. 2002;303(1):36-44.
53. Warms CA, Turner JA, Marshall HM, Cardenas DD. Treatments for chronic pain associated with spinal cord injuries: Many are tried, few are helpful. Clin J Pain. 2002;18(3):154-63.